Sign in to edit your profile (add interests, mentoring, photo, etc.)
    Keywords
    Last Name
    Institution

    Glen D Raffel MD, PhD

    TitleAssistant Professor
    InstitutionUniversity of Massachusetts Medical School
    DepartmentMedicine
    AddressUniversity of Massachusetts Medical School
    364 Plantation Street, LRB
    Worcester MA 01605
      Other Positions
      InstitutionUMMS - Graduate School of Biomedical Sciences
      DepartmentCancer Biology

        Biography 
        awards and honors
        Bowdoin College1986 - 1989James Bowdoin Scholar
        Bowdoin College1989Donald and Harriet Macomber Prize
        Bowdoin College1989Summa cum laude in Biochemistry
        Tufts University School of Medicine1995Allan MacLeod Cormack Award
        Tufts University School of Medicine1998Alpha Omega Alpha
        Tufts University School of Medicine1998William Dameshek Award in Internal Medicine
        2002Diplomate, Internal Medicine, American Board of Internal Medicine
        2004Diplomate, Medical Oncology, American Board of Internal Medicine
        2005Diplomate, Hematology, American Board of Internal Medicine
        Overview 
        Narrative

        The long-term ability of the body’s hematopoietic system to respond to hazardous stressors such as infection, bleeding or cytotoxic chemotherapy ultimately lies with the function of the hematopoietic stem cell (HSC). The defining property of the HSC is self-renewal, allowing replenishment of the cellular blood components over a lifetime. Long-term self-renewing HSCs are maintained in the quiescent G0 phase of the cell cycle through a complex interaction with the bone marrow niche. During proliferative stress, HSCs must enter the cell cycle to generate differentiated progeny to supply the body’s demands. Afterwards, HSCs must be able to return to quiescence, otherwise they will be depleted, leading to bone marrow failure and death. Therefore, pathways controlling the balance between HSC quiescence and proliferation are critically important and tightly regulated. Conversely, these same pathways are often dysregulated in hematopoietic malignancies.Glen Raffell Profile

        The OTT1(aka RBM15) gene was originally isolated as the 5’ fusion partner in the t(1;22)(p13;q13) translocation associated with infant acute megakaryocytic leukemia (AMKL). OTT1 is an ubiquitously expressed member of the spen family of developmental regulators, which are defined by the presence of three RNA-recognition motifs (RRM) and a spen paralog and ortholog (SPOC) domain. Ott1 is believed to be involved with alternative RNA splicing and nuclear export. The SPOC domain confers transcriptional activation/repressor function via an associated Hdac/Ncor/Smrt/Setd1b complex towards currently unknown native targets. A third domain is able to bind the Notch effector, Rbpj, and has been found to activate or repress Notch downstream effectors in a cell context-dependent manner. Constitutive activation through the Notch-effector, RbpJ?, contributes in part, to the oncogenic activity of the t(1;22) fusion product, OTT1-MAL.

        Using a conditional knockout approach in mice and deletion within the hematopoietic compartment, we demonstrated Ott1 has a significant role as a global hematopoietic regulator. Ott1 is required for pre-B development and has inhibitory roles in megakaryocyte, granulocytes and granulocyte/monocyte progenitor development. Although HSC populations are expanded in number after deletion, competitive repopulation experiments showed the HSCs were defective, thus demonstrating that Ott1 is required for HSC function. Further investigations revealed Ott1 is dispensable during steady-state hematopoiesis, however, it is required to maintain quiescence/self-renewal during proliferative stress. We have uncovered roles for Ott1 in the regulation of several processes critical to HSC function including quiescence, control of ROS, stress response and mitochondrial biogenesis. In addition, Ott1-deficient HSCs share many characteristics of prematurely aged HSCs, raising the possibility of Ott1-dependent control of aging-related pathways. The developmental requirement for Ott1 in other tissues such as heart and spleen and its near ubiquitous expression suggest these Ott1-dependent processes may play a more expansive role than confined to hematopoiesis.

        The ability to pharmacologically manipulate HSCs to expand, preserve self-renewal or better tolerate stress is a sought-after goal that would have far-reaching clinical benefits. HSC transplantation is limited by the quantities of available donor cells, particularly from umbilical cord sources, thus enabling in vitro graft expansion while preserving self-renewal capability would be invaluable. HSC exhaustion during cytotoxic chemotherapy is a major dose-limiting toxicity associated with considerable morbidity and mortality especially in the elderly. Likewise, HSCs in inherited and acquired bone marrow failure syndromes are unable to respond adequately to stressors such as infection or anemia.

        We are pursuing the molecular basis underlying the critical functions of Ott1 in hematopoietic and other tissues and how those functions are co-opted in t(1;22) AMKL. Ott1 is involved in control of transcription and splicing and our focus is to ascertain the targets with the aid of mouse genetic models. Our goal is to identify Ott1-dependent pathways important to HSC function to allow development of therapeutic interventions to guard HSC function during stress and impair function in malignant cells.



        Bibliographic 
        selected publications
        List All   |   Timeline
        1. Tam WF, Hähnel PS, Schüler A, Lee BH, Okabe R, Zhu N, Pante SV, Raffel G, Mercher T, Wernig G, Bockamp E, Sasca D, Kreft A, Robinson GW, Hennighausen L, Gilliland DG, Kindler T. STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2. Cancer Res. 2013 Jan 1; 73(1):373-84.
          View in: PubMed
        2. Cerny J, Yu H, Ramanathan M, Raffel GD, Walsh WV, Fortier N, Shanahan L, O'Rourke E, Bednarik J, Barton B, Kroll-Desrosiers A, Hao S, Woda B, Hutchinson L, Evens AM, Rosmarin AG, Nath R. Expression of CD25 independently predicts early treatment failure of acute myeloid leukaemia (AML). Br J Haematol. 2013 Jan; 160(2):262-6.
          View in: PubMed
        3. Xiao N, Jani K, Morgan K, Okabe R, Cullen DE, Jesneck JL, Raffel GD. Hematopoietic stem cells lacking Ott1 display aspects associated with aging and are unable to maintain quiescence during proliferative stress. Blood. 2012 May 24; 119(21):4898-907.
          View in: PubMed
        4. Glen D. Raffel and Jan Cerny. Molecular Biology of Acute Leukemias. Cancer: Principles and Practice of Oncology. Devita, Lawrence and Rosenberg eds. 2011; 1916-1927.
        5. Mercher T, Raffel GD, Moore SA, Cornejo MG, Baudry-Bluteau D, Cagnard N, Jesneck JL, Pikman Y, Cullen D, Williams IR, Akashi K, Shigematsu H, Bourquin JP, Giovannini M, Vainchenker W, Levine RL, Lee BH, Bernard OA, Gilliland DG. The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. J Clin Invest. 2009 Apr; 119(4):852-64.
          View in: PubMed
        6. Raffel GD, Chu GC, Jesneck JL, Cullen DE, Bronson RT, Bernard OA, Gilliland DG. Ott1 (Rbm15) is essential for placental vascular branching morphogenesis and embryonic development of the heart and spleen. Mol Cell Biol. 2009 Jan; 29(2):333-41.
          View in: PubMed
        7. Raffel GD, Mercher T, Shigematsu H, Williams IR, Cullen DE, Akashi K, Bernard OA, Gilliland DG. Ott1(Rbm15) has pleiotropic roles in hematopoietic development. Proc Natl Acad Sci U S A. 2007 Apr 3; 104(14):6001-6.
          View in: PubMed
        For assistance with using Profiles, please refer to the online tutorials or contact UMMS Help Desk or call 508-856-8643.
        Glen's Networks
        Click the "See All" links for more information and interactive visualizations!
        Concepts
        _
        Co-Authors
        _
        Similar People
        _
        Same Department
        Physical Neighbors
        _

        This is an official Page/Publication of the University of Massachusetts Worcester Campus
        Office of the Vice Provost for Research, 55 Lake Ave North, Worcester, Massachusetts 01655
        Questions or Comments? Email: publicaffairs@umassmed.edu Phone: 508-856-1572